Abstract:
Evidence continues to grow that KRAS, once considered an "undruggable" target, can be targeted successfully in non-small cell lung cancer. In a phase I trial, the KRASG12C inhibitor sotorasib elicited responses in about a third of patients with the disease and was generally well tolerated.
Insights
KRAS G12C inhibitors show promise for non-small cell lung cancer. A phase I trial found sotorasib, a KRAS G12C inhibitor, effective and well-tolerated in patients.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- KRAS mutations are prevalent in non-small cell lung cancer (NSCLC).
- The KRAS G12C mutation represents a specific targetable alteration.
- Historically, KRAS has been challenging to target therapeutically.
Discussion:
- Sotorasib is an inhibitor targeting the KRAS G12C mutation.
- A phase I clinical trial evaluated the efficacy and safety of sotorasib.
- The study focused on patients with non-small cell lung cancer harboring the KRAS G12C mutation.
Key Insights:
- Sotorasib demonstrated objective responses in approximately one-third of treated NSCLC patients.
- The KRAS G12C inhibitor was generally well-tolerated, indicating a manageable safety profile.
- These findings support the potential of targeting KRAS G12C in NSCLC.
Outlook:
- Further clinical trials are warranted to confirm these findings in larger patient cohorts.
- Sotorasib may represent a new therapeutic option for a subset of NSCLC patients.
- Continued research into KRAS-targeted therapies holds significant promise for lung cancer treatment.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
8.3K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.3K
02:34Inhibition of Cdk Activity
5.4K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K